Two Sigma Investments LP Buys 54,606 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Two Sigma Investments LP boosted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 13.7% in the fourth quarter, Holdings Channel reports. The firm owned 451,831 shares of the medical research company’s stock after purchasing an additional 54,606 shares during the quarter. Thermo Fisher Scientific accounts for about 0.5% of Two Sigma Investments LP’s investment portfolio, making the stock its 27th largest position. Two Sigma Investments LP’s holdings in Thermo Fisher Scientific were worth $235,056,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Texas Bank & Trust Co acquired a new position in shares of Thermo Fisher Scientific in the 4th quarter valued at approximately $370,000. Tidal Investments LLC raised its position in Thermo Fisher Scientific by 36.9% during the fourth quarter. Tidal Investments LLC now owns 80,346 shares of the medical research company’s stock valued at $41,798,000 after purchasing an additional 21,643 shares in the last quarter. TrinityPoint Wealth LLC lifted its stake in Thermo Fisher Scientific by 7.1% during the fourth quarter. TrinityPoint Wealth LLC now owns 4,242 shares of the medical research company’s stock worth $2,207,000 after purchasing an additional 280 shares during the last quarter. Two Star Manager LLC increased its stake in shares of Thermo Fisher Scientific by 63.6% in the 4th quarter. Two Star Manager LLC now owns 19,793 shares of the medical research company’s stock valued at $10,297,000 after purchasing an additional 7,693 shares during the last quarter. Finally, Strive Asset Management LLC acquired a new position in shares of Thermo Fisher Scientific during the 4th quarter worth $396,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $412.15 on Monday. The business has a 50-day moving average of $453.88 and a 200-day moving average of $509.89. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The company has a market capitalization of $155.58 billion, a price-to-earnings ratio of 24.93, a price-to-earnings-growth ratio of 2.99 and a beta of 0.82. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29.

Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 23rd. The medical research company reported $5.15 EPS for the quarter, beating analysts’ consensus estimates of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to analyst estimates of $10.23 billion. During the same period in the prior year, the firm posted $5.11 EPS. The company’s quarterly revenue was up .2% on a year-over-year basis. As a group, equities research analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th were paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.42%. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. The ex-dividend date was Friday, March 14th. Thermo Fisher Scientific’s payout ratio is currently 10.09%.

Analysts Set New Price Targets

A number of research firms have issued reports on TMO. Stifel Nicolaus decreased their target price on Thermo Fisher Scientific from $665.00 to $620.00 and set a “buy” rating on the stock in a research report on Thursday, April 24th. Argus decreased their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a “buy” rating on the stock in a report on Tuesday, April 29th. Wells Fargo & Company dropped their price objective on shares of Thermo Fisher Scientific from $580.00 to $570.00 and set an “overweight” rating for the company in a research note on Thursday, April 24th. Scotiabank lowered their price target on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a “sector perform” rating for the company in a report on Friday, April 25th. Finally, UBS Group cut their price objective on Thermo Fisher Scientific from $715.00 to $500.00 and set a “buy” rating on the stock in a report on Thursday, April 24th. Five research analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $607.43.

Insider Activity at Thermo Fisher Scientific

In related news, SVP Michael A. Boxer sold 3,775 shares of the business’s stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 10,000 shares of the firm’s stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $516.67, for a total transaction of $5,166,700.00. Following the completion of the sale, the chief executive officer now owns 115,174 shares of the company’s stock, valued at $59,506,950.58. The trade was a 7.99% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 14,075 shares of company stock worth $7,305,942 in the last 90 days. Corporate insiders own 0.33% of the company’s stock.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.